Needham Reiterates Buy on ISIS (ISIS) Following Narrow FDA Vote for Approval of Kynamro

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/14/2026

1. CSCO
2. CBRS
3. COHR
4. SPY
5. EAT
6. WYFI
7. STUB
8. SNDK
9. ARX
10. BTGO

Go back to Needham Reiterates Buy on ISIS (ISIS) Following Narrow FDA Vote for Approval of Kynamro

Jefferies Cuts Numbers on ISIS Pharmaceuticals (ISIS) Despite Panel Backing

October 19, 2012 8:47 AM EDT

Jefferies trimmed its price target on ISIS Pharmaceuticals (NASDAQ: ISIS) from $10 to $8 and kept its Underperform rating despite FDA panel backing of Kynamro.

"While Kynamro commercial potential is low, its approval would validate ISIS' antisense technology platform. However, given numerous side effects... More

Isis Pharmaceuticals (ISIS) Jumps 11% on Trade Resumption

October 18, 2012 5:57 PM EDT

Isis Pharmaceuticals (NASDAQ: ISIS) resumes trading up 11 percent to $10.70 following FDA panel backing.... More

Isis Pharmaceuticals (ISIS) to resume trading at 5:55PM ET

October 18, 2012 5:52 PM EDT

Isis Pharmaceuticals (NASDAQ: ISIS) to resume trading at 5:55PM ET after FDA panel recommends approval of KYNAMRO... More

FDA votes to Approve KYNAMRO for Homozygous Familial Hypercholesterolemia (SNY) (ISIS)

October 18, 2012 5:33 PM EDT

Genzyme, a Sanofi company (NYSE: SNY), and Isis Pharmaceuticals Inc. (NASDAQ: ISIS), announced today that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 9 to 6 that Genzyme had provided sufficient efficacy... More

Isis Pharma (ISIS) Halted Ahead of FDA Committee Meeting for KYNAMRO NDA

October 18, 2012 7:10 AM EDT

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced NASDAQ has halted trading of the Company's common stock. The U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee meets today to review the new drug application (NDA) for KYNAMRO for the treatment of patients with homozygous... More